A propósito de un consenso colombiano sobre enfermedad medible residual en neoplasias hematológicas
A Purpose of a Colombian Consensus on Minimal Measurable Disease in Hematologic Neoplasms
Sección
Editorial
Cómo citar
A propósito de un consenso colombiano sobre enfermedad medible residual en neoplasias hematológicas .
Rev. colomb. hematol. oncol. [Internet]. 2024 Dec. 5 [cited 2024 Dec. 30];11(2):9-11. Disponible en: https://doi.org/10.51643/22562915.733
Dimensions
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Mostrar biografía de los autores
Visitas del artículo 65 | Visitas PDF 41
- Niederberger M and Spranger J. Delphi Technique in Health Sciences: A Map. Front. Public Health.2020 (8):1-10 Disponible en: https://doi.org/10.3389/fpubh.2020.00457
- Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: How to decide its appropriateness. World J Methodol. 2021 Jul 20;11(4):116-129. Disponible en: https://doi.org/10.5662/wjm.v11.i4.116
- Bruggemann M, Raff T, Kneba M. Has MRD monitoring superseded other prognostic factors in adult ALL. Blood. 2012; 120(23):4470-4481. Disponible en: https://doi.org/10.1182/blood-2012-06-379040
- Berry DA, Zhou S, Higley H. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017; 3(7):e170580. Disponible en: https://doi.org/10.1001/jamaoncol.2017.0580
- Heuser M, Freeman D, Ossenkoppele Gert, Buccisano F, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European Leukemia Net MRD Working Party. Blood 2021; 138 (26): 2753–2767. Disponible en: https://doi.org/10.1182/blood.2021013626
- Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988-5999. Disponible en: https://doi.org/10.1182/bloodadvances.2020002827
- Shimony S, Stahl M, Stone R. Acute myeloid leukemia: 2023 update on diagnosis risk-stratification, and management. Am J Hematol. 2023; 98:502–526. Disponible en: https://doi.org/10.1002/ajh.26822
- Gökbuget N, Boissel N, Chiaretti S, Dombret H, Michael Doubek, et al. Management of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood 2024; 143 (19): 1903–1930. Disponible en: https://doi.org/10.1182/blood.2023023568
- Othus M, Gale RP, Hourigan C, Walter R; Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic stem cell transplantation. Bone Marrow Transplantation (2020) 55:843–850. –850. Disponible en: https://doi.org/10.1038/s41409-019-0729-4
- Litzow M, Sun Z, Mattison R, Paietta E, et al. Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. N Engl J Med 2024; 391:320-333 Disponible en: https://doi.org/10.1056/NEJMoa2312948
- Meseha M, Hoffman J, Kazandjian D, Landgren O, et al. Minimal Residual Disease Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions. Current Oncology Reports (2024) 26:679–690. Disponible en: https://doi.org/10.1007/s11912-024-01537-2
Información
Directorios e indexadores
Perfil de Google Scholar
Código QR
Palabras clave
Más leídos en los últimos 30 días
